Vanderbilt University Med Ctr — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$8,781	1
2021	Research	$170,869	2
2020	Research	$193,813	6
2019	Research	$57,325	4

Breakdown

Who paid Research payments · program years 2019–2022

Pfizer Inc. $336,761 4 payments
Astellas Pharma Global Development $85,245 8 payments
Genentech, Inc. $8,781 1 payment

Studies the money was for Research payments · program years 2019–2022

Provision of Free Varenicline Chantix Within the Context of A Dedicated Outpatient Tobacco Treatment Clinic TTC for Cancer Patients $336,761 4 payments
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3ITD AML $57,325 4 payments
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the Flt3 Inhibitor Gilteritinib Administered As Maintenance Therapy Following Allogeneic Transplant for Patients With Flt3/Itd Aml $27,920 4 payments
Phase Ia Ib Study of GDC 9545 Palbociclib LHRH Agonist in With Patients Er BC $8,781 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.